Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158138 | 0.82 | MEN1 (0.35) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL4155338 | 0.79 | MEN1 (0.37) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL4150005 | 0.75 | — | — | |
| SCHEMBL4157937 | 0.72 | ESR1 (0.34) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL4158524 | 0.69 | LMNA (0.32) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL13105763 | 0.69 | TAS2R14 (0.39) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL8095674 | 0.68 | IDO1 (0.39) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL4150588 | 0.68 | PTGS2 (0.31) | MEN1ALOX15TSHRMAPK1KMT2A | |
| SCHEMBL16707489 | 0.65 | ALDH1A1 (0.37) | SMN1; SMN2 | |
| SCHEMBL4141986 | 0.65 | KIF11 (0.41) | ALOX15TSHRHSD17B10LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176786-A1 | Benzoylurea Compounds and Use Thereof | BTK, BRIX1, NFXL1 | MEN1 1863/4885ALOX15 3375/4885TSHR 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.